ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers? - Pharmaceutical Technology

ESMO 2022: neoadjuvant or adjuvant immunotherapy for locally advanced cancers?  Pharmaceutical Technology